<DOC>
	<DOCNO>NCT02152280</DOCNO>
	<brief_summary>Research topic . - A clinical trial Danhong injection treat acute ischemic stroke . Research purpose . - To evaluate efficacy safety Danhong injection treat acute ischemic stroke randomize , double-blind , multi-center , placebo-controlled clinical trial . Research design . - A randomized , double-blind , multi-center , placebo-controlled clinical trial . Subject crowd . - Accord standard western medicine diagnosis acute cerebral infarction , stroke blood stasis type traditional Chinese medicine syndrome differentiation . Sample size . - Total sample size 320 patient , experimental group , control group equal 1 1 . Interim analysis . - Interim analysis perform total number include patient half sample size ,160 case , accord interim analysis result estimate sample size adjust project adaptively . Course treatment . - 10 day . Research endpoint . - The 90th day medication first time . Observation index . 1 . General condition ; physical chemical inspection relate ; 2 . Efficacy check : mRS , BI , NIHSS ; 3 . Safety check : blood routine , urine routine , stool OB , liver function ( ALT、AST ) , renal function ( BUN , Cr ) , coagulation four indices（PT、APTT、TT、FIB ) , electrocardiogram . Efficacy evaluation . 1 . The main efficacy index : . Percentage comparison two group patient modify Rankin 0-2 grade 90th day . Statistical analysis technique . - Statistical analysis use SAS 9.2 system , statistical test adopt bilateral inspection , P value less equal 0.05 consider statistically significant difference .</brief_summary>
	<brief_title>A Clinical Trial Danhong Injection Treating Acute Ischemic Stroke</brief_title>
	<detailed_description>Research topic . - A clinical trial Danhong injection treat acute ischemic stroke . Research purpose . - To evaluate efficacy safety Danhong injection treat acute ischemic stroke randomize , double-blind , multi-center , placebo-controlled clinical trial . Research design . - A randomized , double-blind , multi-center , placebo-controlled clinical trial . Subject crowd . - Accord standard western medicine diagnosis acute cerebral infarction , stroke blood stasis type traditional Chinese medicine syndrome differentiation . Sample size . - Total sample size 320 patient , experimental group , control group equal 1 1 . Interim analysis . - Interim analysis perform total number include patient half sample size ,160 case , accord interim analysis result estimate sample size adjust project adaptively . Inclusion criterion . 1 . Accord diagnostic criterion cerebral infarction `` Guide diagnosis treatment acute ischemic stroke China '' 2010 , acute stage ; 2 . Accord stroke blood stasis type ; 3 . Onset acute ischemic stroke within 72 hour ; 4 . NIHSS grade ≥ 4 ; 5 . Age ≥ 18 ; 6. sign inform consent form . Exclusion criterion . 1 . Diagnosed bleed pathological brain disorder accord CT MRI baseline , vascular malformation , tumor , abscess common non ischemic cerebral disease ( multiple sclerosis ) ; 2 . Patients hrombolysis endovascular treatment ; 3 . Allergic constitution ; test drug allergy ingredient elements allergy ; 4 . With severe liver function damage ( ALT AST level 1.5 time higher normal ) ; 5 . With severe renal impairment ( 1.5 time higher normal amount serum creatinine ) ; 6 . With severe cardiac insufficiency ( cardiac function rating level III ) ; 7 . Disabled patient law ( blind , deaf , dumb , mental retardation , mental disorder physical disability cause reason affect nerve function defect evaluation ) ; 8 . With bleed tendency serious bleeding within 3 month ; 9 . Doubted alcohol drug abuse history ; Or low possibility enrollment complicate enrollment accord investigaters ' judgement ; 10 . Menstrual period woman , pregnant woman lactate woman , pregnancy test positive recent family planning ; 11. Who clinical trial finish clinical trial within 3 month . Dosage regimen . 1 . Experimental group : Danhong injection 40 ml add 250 ml 0.9 % sodium chloride solution , injection intravenous drip , 1 time day , 10 day ; 2 . Control group : 0.9 % sodium chloride solution 40 ml add 250 ml 0.9 % sodium chloride solution , injection intravenous drip , 1 time day , 10 day . Course treatment . - 10 day . Research endpoint . - The 90th day medication first time . Observation index . 1 . General condition ; physical chemical inspection relate ; 2 . Efficacy check : mRS , BI , NIHSS ; 3 . Safety check : blood routine , urine routine , stool OB , liver function ( ALT、AST ) , renal function ( BUN , Cr ) , coagulation four indices（PT、APTT、TT、FIB ) , electrocardiogram . Observation point . 1 . The physical chemical inspection relate electrocardiogram observe enrollment time ; 2 . General condition efficacy index observe 10th ,90th medication first time ; 3 . Safety index observe 10th medication first time . Efficacy evaluation . 1 . The main efficacy index : 1 . Percentage comparison two group patient modify Rankin 0-2 grade 90th day . 2 . The secondary efficacy index : 1 . Mortality comparison two group patient 90th day ; 2 . Percentage comparison two group patient BI≥75 90th day ; 3 . NIHSS difference comparison two group 90th day ; 4 . The proportion new vascular event within 3 month ( Ischemic stroke/hemorrhagic stroke/TIA/MI/vascular death ) . Safety evaluation . 1 . All-Cause mortality within 90 day : death toll cause within 90 days/ total number group × 100 % ; 2 . Incidence serious bleed event ( GUSTO definition , appendix 4 ) , include fatal bleeding symptomatic intracranial bleeding ; 3 . Incidence moderate bleeding event ( GUSTO definition , appendix 4 ) ; 4 . Adverse event serious adverse event report investigaters . Statistical analysis technique . - Statistical analysis use SAS 9.2 system , statistical test adopt bilateral inspection , P value less equal 0.05 consider statistically significant difference .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Accord diagnostic criterion cerebral infarction `` Guide diagnosis treatment acute ischemic stroke China '' 2010 , acute stage ; Accord stroke blood stasis type ; Onset acute ischemic stroke within 72 hour ; NIHSS grade ≥ 4 ; Age ≥ 18 ; sign inform consent form . Diagnosed bleed pathological brain disorder accord CT MRI baseline , vascular malformation , tumor , abscess common non ischemic cerebral disease ( multiple sclerosis ) ; Patients hrombolysis endovascular treatment ; Allergic constitution ; test drug allergy ingredient elements allergy ; With severe liver function damage ( ALT AST level 1.5 time higher normal ) ; With severe renal impairment ( 1.5 time higher normal amount serum creatinine ) ; With severe cardiac insufficiency ( cardiac function rating level III ) Disabled patient law ( blind , deaf , dumb , mental retardation , mental disorder physical disability cause reason affect nerve function defect evaluation ) ; With bleeding tendency serious bleeding within 3 month ; Doubted alcohol drug abuse history ; Or low possibility enrollment complicate enrollment accord investigaters ' judgement ; Menstrual period woman , pregnant woman lactate woman , pregnancy test positive recent family planning ; Who clinical trial finish clinical trial within 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>